Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection;Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Cumulative Incidence of Grade 3 and 4 Adverse Events;Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Number of Participants With "Serious Adverse Events"

Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection;Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Cumulative Incidence of Grade 3 and 4 Adverse Events;Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Number of Participants With "Serious Adverse Events"

Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1;Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2;Efficacy of treatment at Day 28

Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1;Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2;Efficacy of treatment at Day 28